最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关于使用部分闲置自有资金进行现金管理的实施公告》 《第七届董事会第二次会议决议公告》 《关于收购亳州爱尔、连云港爱尔等39家机构部分股权的公告》 截至2025年12月25日收盘，爱尔眼科（300015）报收于11.14元，较前一交易日上涨0.18%，最新总市值 为1038.85亿元。该股当日开盘11.15元，最高11.17元，最低11.05元，成交额达4.32亿元，换手率为 0.49%。 近日，爱尔眼科医院集团股份有限公司召开第七届董事会第二次会议，审议通过《关于收购亳州爱尔、 连云港爱尔等39家机构部分股权的议案》。公司拟以自有资金96,302.28万元收购39家医疗机构部分股 权。本次收购不构成关联交易，亦不构成重大资产重组，无需提交股东大会审议。收购完成后，公司将 持有各标的医院不同比例的股权，进一步完善分级连锁体系，提升市场竞争力。标的公司主要分布于地 市级和县级区域，有助于落实分级诊疗政策，推动优质医疗资源下沉。 ...

12月24日晚间，爱尔眼科（300015）公告称，公司第七届董事会第二次会议审议通过《关于收购亳州爱 尔、连云港爱尔等39家机构部分股权的议案》，本次交易以自有资金支付，交易合计金额为9.63亿元。 本次交易不构成关联交易，不构成重大资产重组。本次交易未达到股东会议事范围，经公司董事会审议 批准后即可实施。 整体来看，39家眼科医疗机构除青海爱尔属省会医院外，其余均为地市级及县级机构，在收购完成后， 爱尔眼科 对其持股比例处于51%至100%之间。公告显示，39家标的公司2024年的整体收入68589.73万 元，净利润-5899.51万元；2025年1月~9月的整体收入58782.77万元，净利润2024.59万元，大部分标的 公司正处在扭亏为盈的拐点阶段。 对于此次收购标的聚焦下沉市场， 爱尔眼科 表示，是进一步完善公司分级连锁体系，加强市场领先地 位的需要，具有必要性。同时，可充分发挥协同效应与规模效应，持续提升盈利能力与综合竞争力，并 落实国家"分级诊疗"政策导向，提高基层居民就医的可及性。 数据显示，中国地市县域人口占总人口的七成以上，眼科需求持续增长，但优质医疗供给不足。长期以 来， 爱尔眼科 将 ...

公司本次收购39家机构的部分股权，有利于尽快完善区域市场布局，形成规模效应，进一步深化在全国 各地的"分级连锁"体系，巩固和提升公司的领先地位。 爱尔眼科（300015）(300015.SZ)发布公告，公司于2025年12月24日召开第七届董事会第二次会议，审 议通过《关于收购亳州爱尔、连云港爱尔等39家机构部分股权的议案》，本次交易以自有资金支付，交 易合计金额为9.63亿元。 ...

Core Viewpoint - The company reported a slight decline in net profit due to strategic layout impacts, despite a steady revenue growth in the first three quarters of 2025 [1][3]. Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 17.484 billion yuan, a year-on-year increase of 7.25%, while the net profit attributable to shareholders was 3.115 billion yuan, a year-on-year decrease of 9.76% [1]. - In the third quarter of 2025, the company recorded a revenue of 5.977 billion yuan, a year-on-year increase of 3.8%, and a net profit of 1.064 billion yuan, a year-on-year decrease of 24.1% [2]. - The gross profit margin for the third quarter was 50.65%, down 3.3 percentage points year-on-year, attributed to increased depreciation and amortization expenses from new hospital openings [3]. Business Segments - The refractive and optical business showed strong performance, with an increase in revenue driven by a higher proportion of new surgical methods and stable pricing [2]. - The cataract project experienced a slight revenue decline due to medical insurance cost control, although the average revenue per case showed a small recovery [2]. - The eye disease project maintained stable overall revenue despite a decrease in average revenue per case due to medical insurance cost control [2]. Strategic Developments - The company announced the acquisition of three hospitals for a total of 105 million yuan, which is expected to enhance its "graded chain" development model and improve its operational layout [2]. Profit Forecast and Valuation - The company adjusted its net profit forecasts for 2025 and 2026 downwards by 14.4% and 14.7% to 3.50 billion yuan and 4.01 billion yuan, respectively, due to anticipated increases in depreciation and amortization from new hospital openings [4]. - The current stock price corresponds to a P/E ratio of 32.8x for 2025 and 28.7x for 2026, with a target price of 16.0 yuan, indicating a potential upside of 29.9% [4].

Core Viewpoint - The company reported a revenue of 20.98 billion yuan for 2024, with a year-on-year growth of 3.0%, and net profits meeting market expectations. The first quarter of 2025 showed a revenue of 6.03 billion yuan, a year-on-year increase of 16.0%, exceeding market expectations, primarily due to the recovery in consumer business [1]. Group 1: Business Performance - In 2024, the consumer business faced pressure, with refractive and optical revenues growing by 2.3% and 6.4% year-on-year, respectively. However, in Q1 2025, both segments are expected to outperform the overall company revenue growth due to the elimination of price base pressure and the application of new technologies [2]. - The serious medical segment maintained stable growth in 2024, with cataract, anterior segment, and posterior segment revenues increasing by 4.9%, 5.9%, and 8.2% year-on-year, respectively. The company anticipates continued stable performance in Q1 2025 [2]. Group 2: Expansion and Service Improvement - By the end of 2024, the company operated 581 domestic medical institutions and 163 overseas institutions, having acquired nearly 90 domestic medical institutions and the Optimax Group to enter the UK ophthalmology market. This expansion is expected to enhance market positioning and achieve economies of scale [3]. - The company is optimizing service models by extending outpatient hours and building smart hospital platforms to meet diverse patient needs, achieving a patient satisfaction rate close to 99.0% in 2024 [3]. Group 3: Financial Metrics - In 2024, the company reported a gross margin of 48.1%, a sales expense ratio of 10.3%, and a management expense ratio of 14.2%. The net profit margin for the parent company was 16.9% [4]. - In Q1 2025, the company achieved a gross margin of 48.0%, with a reduction in sales and management expense ratios to 9.0% and 12.6%, respectively. The net profit margin for the parent company increased to 17.6% year-on-year [4]. Group 4: Profit Forecast and Valuation - The company adjusted its net profit forecast for 2025-2026 down by 7.73% and 7.94% to 4.09 billion yuan and 4.699 billion yuan, respectively. The current stock price corresponds to a P/E ratio of 29.9x for 2025 and 26.0x for 2026 [5]. - The target price is maintained at 16.0 yuan, corresponding to a P/E ratio of 36.5x for 2025 and 31.8x for 2026, indicating a potential upside of 22.0% from the current stock price [5].